Management & Regulatory

While digital modalities are frequently perceived as mere supplements to care, recent data suggests they function as equivalent alternatives to standard clinical therapies across twelve distinct medical categories. This conclusion is bolstered by a comprehensive umbrella review of meta-analyses

Any project seeking to increase the virulence or transmissibility of a biological agent faces immediate federal funding restrictions under the strict definitions of the new Stopping Policy guidelines. This regulatory pivot, formalized in mid-2026, marks the end of an era where oversight was

Aged care remains a secondary consideration in the National Healthcare Interoperability Plan 2023-2028 despite the broader healthcare system achieving an eighty percent completion rate. This disparity highlights a significant vulnerability in Australia’s health infrastructure as the sector

After nearly four decades of operation under the same regulatory framework, Andorra is transitioning its medical system toward a meritocratic leadership model focused on specialized expertise. This sweeping legislative initiative, introduced by Health Minister Helena Mas, represents a foundational

The global medical supply chain relies heavily on Indian manufacturing, making any shift in domestic pharmaceutical regulations a matter of international concern for healthcare providers and patients alike. The Ministry of Health recently proposed rigorous amendments to the Drugs Rules, signaling a

The Carlsbad facility brings end-to-end viral vector solutions and aseptic fill-finish capabilities to Lonza, catering specifically to the burgeoning cell and gene therapy market. This strategic acquisition of five specialized contract development and manufacturing organization (CDMO) sites from